Glucotrack Subsidiary Lōkahi Therapeutics Engaged Two ai² PIPELINE Project Teams To Identify And Evaluate Brain Tumor Therapeutic Assets Available For Licensing And Development
Innovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and developmentLōkahi Therapeutics™ Inc., a
Glucotrack's brain tumor company hired expert teams to find treatments to buy or develop. This shows the company is actively hunting for new medicine ideas to grow its business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.